<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Plant Biotechnol J</journal-id><journal-id journal-id-type="iso-abbrev">Plant Biotechnol. J</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1467-7652</journal-id><journal-id journal-id-type="publisher-id">PBI</journal-id><journal-title-group><journal-title>Plant Biotechnology Journal</journal-title></journal-title-group><issn pub-type="ppub">1467-7644</issn><issn pub-type="epub">1467-7652</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6917977</article-id><article-id pub-id-type="doi">10.1111/pbi.13194</article-id><article-id pub-id-type="publisher-id">PBI13194</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>
<italic>In vitro and in vivo</italic> efficacy of anti&#x02010;chikungunya virus monoclonal antibodies produced in wild&#x02010;type and glycoengineered <italic>Nicotiana benthamiana</italic> plants</article-title><alt-title alt-title-type="right-running-head">Glycoengineered anti&#x02010;Chikungunya monoclonal antibody</alt-title><alt-title alt-title-type="left-running-head">Jonathan Hurtado <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="pbi13194-cr-0001" contrib-type="author"><name><surname>Hurtado</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="pbi13194-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="pbi13194-cr-0002" contrib-type="author"><name><surname>Acharya</surname><given-names>Dhiraj</given-names></name><xref ref-type="aff" rid="pbi13194-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="pbi13194-cr-0003" contrib-type="author"><name><surname>Lai</surname><given-names>Huafang</given-names></name><xref ref-type="aff" rid="pbi13194-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="pbi13194-cr-0004" contrib-type="author"><name><surname>Sun</surname><given-names>Haiyan</given-names></name><xref ref-type="aff" rid="pbi13194-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="pbi13194-cr-0005" contrib-type="author"><name><surname>Kallolimath</surname><given-names>Somanath</given-names></name><xref ref-type="aff" rid="pbi13194-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="pbi13194-cr-0006" contrib-type="author"><name><surname>Steinkellner</surname><given-names>Herta</given-names></name><xref ref-type="aff" rid="pbi13194-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="pbi13194-cr-0007" contrib-type="author"><name><surname>Bai</surname><given-names>Fengwei</given-names></name><xref ref-type="aff" rid="pbi13194-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="pbi13194-cr-0008" contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Qiang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1498-7013</contrib-id><xref ref-type="aff" rid="pbi13194-aff-0001">
<sup>1</sup>
</xref><address><email>qiang.chen.4@asu.edu</email></address></contrib></contrib-group><aff id="pbi13194-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">The Biodesign Institute and School of Life Sciences</named-content>
<institution>Arizona State University</institution>
<city>Tempe</city>
<named-content content-type="country-part">AZ</named-content>
<country country="US">USA</country>
</aff><aff id="pbi13194-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Cell and Molecular Biology</named-content>
<institution>University of Southern Mississippi</institution>
<city>Hattiesburg</city>
<named-content content-type="country-part">MS</named-content>
<country country="US">USA</country>
</aff><aff id="pbi13194-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Applied Genetics and Cell Biology</named-content>
<institution>University of Natural Resources and Applied Life Sciences</institution>
<city>Vienna</city>
<country country="AT">Austria</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence</italic> (Tel 480 239 7802; fax 480 727 7615; email <email>qiang.chen.4@asu.edu</email>)</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2020</year></pub-date><volume>18</volume><issue>1</issue><issue-id pub-id-type="doi">10.1111/pbi.v18.1</issue-id><fpage>266</fpage><lpage>273</lpage><history><date date-type="received"><day>09</day><month>2</month><year>2019</year></date><date date-type="rev-recd"><day>21</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>02</day><month>6</month><year>2019</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2019 The Authors. <italic>Plant Biotechnology Journal</italic> published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:PBI-18-266.pdf"/><abstract id="pbi13194-abs-0001"><title>Summary</title><p>Chikungunya virus (<styled-content style="fixed-case" toggle="no">CHIKV</styled-content>) is a mosquito&#x02010;transmitted alphavirus, and its infection can cause long&#x02010;term debilitating arthritis in humans. Currently, there are no licensed vaccines or therapeutics for human use to combat <styled-content style="fixed-case" toggle="no">CHIKV</styled-content> infections. In this study, we explored the feasibility of using an anti&#x02010;<styled-content style="fixed-case" toggle="no">CHIKV</styled-content> monoclonal antibody (<styled-content style="fixed-case" toggle="no">mA</styled-content>b) produced in wild&#x02010;type (<styled-content style="fixed-case" toggle="no">WT</styled-content>) and glycoengineered (&#x02206;<styled-content style="fixed-case" toggle="no">XFT</styled-content>) <italic>Nicotiana benthamiana</italic> plants in treating <styled-content style="fixed-case" toggle="no">CHIKV</styled-content> infection in a mouse model. <styled-content style="fixed-case" toggle="no">CHIKV mA</styled-content>b was efficiently expressed and assembled in plant leaves and enriched to homogeneity by a simple purification scheme. While <styled-content style="fixed-case" toggle="no">mA</styled-content>b produced in &#x02206;<styled-content style="fixed-case" toggle="no">XFT</styled-content> carried a single N&#x02010;glycan species at the Fc domain, namely GnGn structures, <styled-content style="fixed-case" toggle="no">WT</styled-content> produced <styled-content style="fixed-case" toggle="no">mA</styled-content>b exhibited a mixture of N&#x02010;glycans including the typical plant GnGn<styled-content style="fixed-case" toggle="no">XF</styled-content>
<sub>3</sub> glycans, accompanied by incompletely processed and oligomannosidic structures. Both <styled-content style="fixed-case" toggle="no">WT</styled-content> and &#x02206;<styled-content style="fixed-case" toggle="no">XFT</styled-content> plant&#x02010;produced <styled-content style="fixed-case" toggle="no">mA</styled-content>bs demonstrated potent <italic>in vitro</italic> neutralization activity against <styled-content style="fixed-case" toggle="no">CHIKV</styled-content>. Notably, both <styled-content style="fixed-case" toggle="no">mA</styled-content>b glycoforms showed <italic>in vivo</italic> efficacy in a mouse model, with a slight increased efficacy by the &#x02206;<styled-content style="fixed-case" toggle="no">XFT</styled-content>&#x02010;produced <styled-content style="fixed-case" toggle="no">mA</styled-content>bs. This is the first report of the efficacy of plant&#x02010;produced <styled-content style="fixed-case" toggle="no">mA</styled-content>bs against <styled-content style="fixed-case" toggle="no">CHIKV</styled-content>, which demonstrates the ability of using plants as an effective platform for production of functionally active <styled-content style="fixed-case" toggle="no">CHIKV mA</styled-content>bs and implies optimization of <italic>in vivo</italic> activity by controlling Fc glycosylation.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="pbi13194-kwd-0001">monoclonal antibody</kwd><kwd id="pbi13194-kwd-0002">chikungunya virus</kwd><kwd id="pbi13194-kwd-0003">plant&#x02010;made therapeutics</kwd><kwd id="pbi13194-kwd-0004">glycosylation</kwd><kwd id="pbi13194-kwd-0005">neutralization</kwd><kwd id="pbi13194-kwd-0006">glycoengineering</kwd><kwd id="pbi13194-kwd-0007">plant&#x02010;made antibody</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institute of Allergy and Infectious Diseases </institution><institution-id institution-id-type="open-funder-registry">10.13039/100000060</institution-id></institution-wrap></funding-source><award-id>R33AI101329</award-id><award-id>R15A113706</award-id><award-id>R15AI135893</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="1"/><page-count count="8"/><word-count count="6550"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.3 mode:remove_FC converted:18.12.2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="pbi13194-body-0001"><sec id="pbi13194-sec-0001"><title>Introduction</title><p>Chikungunya virus (CHIKV) is a positive&#x02010;sense RNA virus belonging to the alphavirus family, which can be transmitted to humans by mosquitoes. The viral RNA is encapsulated in a central capsid core, which, in turn, is surrounded by the viral envelope studded with viral envelope proteins 1 and 2 (E1 and E2) (Voss <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0044" ref-type="ref">2010</xref>). Infection of CHIKV in humans can cause debilitating polyarthralgia that may persist months to years and affects multiple joints including ankles, knees, wrists and fingers (Schilte <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0038" ref-type="ref">2013</xref>). Since 2004, CHIKV reemergence has resulted in millions of cases of severe and often chronic arthralgia on five continents (Weaver and Forrester, <xref rid="pbi13194-bib-0045" ref-type="ref">2015</xref>). Currently, there are no licensed therapeutics or vaccines against CHIKV for human use. Continued outbreaks of CHIKV and the risk of it spreading into new areas call for the urgent development of therapeutics to treat this debilitating virus.</p><p>The potential utility of antibodies as efficacious anti&#x02010;CHIKV therapeutics was suggested by early vaccine studies. It was found that vaccine potency correlates with its ability of inducing neutralizing antibodies in mice. Neutralizing antibodies from past infections in humans also show evidence of protectivity, as these subjects are immune to CHIKV reinfection (Kam <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0022" ref-type="ref">2012</xref>; Yoon <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0049" ref-type="ref">2015</xref>). Indeed, monoclonal antibodies (mAbs) against CHIKV E1 and E2 have been shown to be protective against CHIKV infection in various mouse models. For example, anti&#x02010;E1 or E2 mAbs protected immune compromised (Ifnar &#x02010;/&#x02010;) mice against lethal challenges of CHIKV when given as post&#x02010;exposure therapy (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>). Interestingly, it was also revealed that in addition to neutralizing potency, antibody Fc effector functions also contribute to the efficacy of anti&#x02010;CHIKV E1 and E2 antibodies (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>).</p><p>Plants have been demonstrated to be an attractive alternative to mammalian cell cultures as a system for mAb development and production (Chen and Davis, <xref rid="pbi13194-bib-0007" ref-type="ref">2016</xref>). mAbs produced in <italic>Nicotiana benthamiana</italic> have been developed as candidates to treat various viral infections including those caused by West Nile virus (WNV) (Sun <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0042" ref-type="ref">2018</xref>), dengue virus (DENV) (Dent <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0012" ref-type="ref">2016</xref>) and, of prominence, using a cocktail of three mAbs to treat Ebola virus&#x02010;infected human patients (PREVAIL Group, <xref rid="pbi13194-bib-0035" ref-type="ref">2016</xref>). For example, we have demonstrated that a single dose of an anti&#x02010;WNV mAb produced in <italic>N.&#x000a0;benthamiana</italic> and lettuce plants protected mice from lethal infection of WNV, even given 4&#x000a0;days post&#x02010;infection (dpi) when virus already circulates in the brain (He <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0017" ref-type="ref">2014</xref>; Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0025" ref-type="ref">2010</xref>, <xref rid="pbi13194-bib-0026" ref-type="ref">2012</xref>, <xref rid="pbi13194-bib-0027" ref-type="ref">2014</xref>).</p><p>One of the advantages of using plants for the production of glycoproteins is that they are highly amenable to glycoengineering, which allows the generation of proteins with tailor&#x02010;made N&#x02010;glycans (Montero&#x02010;Morales and Steinkellner, <xref rid="pbi13194-bib-0033" ref-type="ref">2018</xref>). This is particularly relevant to mAbs since it is well known that the glycosylation profile on the single N&#x02010;glycosylation site in the Fc domain of IgG antibodies significantly impacts mAb activities (Jefferis, <xref rid="pbi13194-bib-0021" ref-type="ref">2012</xref>). For example, the targeted removal of core fucose residues from complex N&#x02010;glycans in mammalian and plant&#x02010;produced IgGs significantly increases Fc gamma receptor (Fc&#x003b3;R) III binding and subsequent effector functions. This has been demonstrated impressively for anti&#x02010;cancer antibodies, where the first generation of glycan&#x02010;engineered antibody therapeutics is ready to emerge on the market (Garber, <xref rid="pbi13194-bib-0014" ref-type="ref">2018</xref>; Reichert, <xref rid="pbi13194-bib-0036" ref-type="ref">2012</xref>). However, related studies for antibodies against infectious diseases are rare (Forthal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0013" ref-type="ref">2010</xref>), with only a few <italic>in vivo</italic> studies demonstrating increased antiviral activity of glycan&#x02010;engineered mAbs in murine challenging models (Hiatt <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0018" ref-type="ref">2014</xref>; Zeitlin <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0051" ref-type="ref">2011</xref>). Nevertheless, the impact of glycosylation to antiviral antibody&#x02010;induced effector functions is still under debate, as non&#x02010;human primate studies of anti&#x02010;HIV antibodies did not show glycan&#x02010;dependent efficacy (Moldt <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0032" ref-type="ref">2012</xref>).</p><p>Here, we aimed to produce two glycoforms of anti&#x02010;CHIKV E1 mAb (CHKVmab) in plants and investigate their <italic>in vitro</italic> and <italic>in vivo</italic> efficacy. CHKVmabs were efficiently expressed and assembled in wild&#x02010;type (WT) <italic>N.&#x000a0;benthamiana</italic>, as well as in &#x02206;XFT, a <italic>N.&#x000a0;benthamiana</italic> glycosylation mutant lacking plant&#x02010;specific core xylose and fucose. &#x02206;XFT&#x02010;derived CHKVmab (&#x02206;XFpCHKVmab) exhibited mammalian&#x02010;type GnGn glycans with high uniformity, while WT&#x02010;produced CHKVmab (WTpCHKVmab) carried a mixture of N&#x02010;glycans, including typical plant GnGnXF<sub>3</sub>, incompletely processed and oligomannosidic structures. Both mAb variants potently neutralized CHIKV <italic>in vitro</italic>. Notably, both pCHKVmab glycoforms also showed efficacy but with different potency against CHIKV infection in a murine model.</p></sec><sec sec-type="results" id="pbi13194-sec-0002"><title>Results</title><sec id="pbi13194-sec-0003"><title>Expression and assembly of CHKVmab in WT and &#x00394;XF <italic>N.&#x000a0;benthamiana</italic> plants</title><p>The DNA expression cassette of the heavy chain (HC) and light chain (LC) of CHKVmab was cloned into a MagnICON&#x02010;based plant expression vector (Giritch <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0015" ref-type="ref">2006</xref>), transformed into <italic>Agrobacterium tumefaciens</italic> and agroinfiltrated into WT and &#x02206;XFT <italic>N.&#x000a0;benthamiana</italic> leaves (Chen and Lai, <xref rid="pbi13194-bib-0008" ref-type="ref">2014a</xref>; Leuzinger <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0029" ref-type="ref">2013</xref>). The expression of CHKVmab was evaluated by Western blot analysis. As shown in Figure&#x000a0;<xref rid="pbi13194-fig-0001" ref-type="fig">1</xref>, WTpCHKVmab and &#x02206;XFpCHKVmab have HC and LC with the expected molecular weight (Figure&#x000a0;<xref rid="pbi13194-fig-0001" ref-type="fig">1</xref>a,b, Lanes 3&#x02013;4), and are fully assembled into the heterotetramer equivalent to a positive control IgG (Figure&#x000a0;<xref rid="pbi13194-fig-0001" ref-type="fig">1</xref>c, Lanes 3&#x02013;4). The expression level of WTpCHKVmab and &#x02206;XFpCHKVmab was estimated to be 100 and 130&#x000a0;&#x003bc;g/g leaf fresh weight (LFW), respectively. This level of expression is similar to that previously reported for non&#x02010;codon&#x02010;optimized mAbs produced in plants (De Muynck <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0011" ref-type="ref">2010</xref>; Dent <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0012" ref-type="ref">2016</xref>; Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0025" ref-type="ref">2010</xref>).</p><fig fig-type="Figure" xml:lang="en" id="pbi13194-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Western blot analysis of plant&#x02010;produced <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab. <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab was extracted from <styled-content style="fixed-case" toggle="no">WT</styled-content> or &#x02206;<styled-content style="fixed-case" toggle="no">XFT </styled-content>
<italic>Nicotiana benthamiana</italic> leaves, separated on <styled-content style="fixed-case" toggle="no">SDS</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">PAGE</styled-content> gels under reducing (a and b) or non&#x02010;reducing (c) conditions, and blotted onto <styled-content style="fixed-case" toggle="no">PVDF</styled-content> membranes. A goat anti&#x02010;human gamma chain antibody (a) or a goat anti&#x02010;human kappa chain antibody (b and c) was incubated with the membranes to detect heavy chain or light chain. Lane 1, protein sample extracted from non&#x02010;infiltrated leaves; Lane 2, mammalian cell&#x02010;produced anti&#x02010;<styled-content style="fixed-case" toggle="no">WNV</styled-content> E16 <styled-content style="fixed-case" toggle="no">mA</styled-content>b as a reference standard; Lane 3, sample from leaves of <styled-content style="fixed-case" toggle="no">WT</styled-content> plants infiltrated with <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab constructs; Lane 4, sample from leaves of &#x02206;<styled-content style="fixed-case" toggle="no">XFT</styled-content> plants infiltrated with <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab constructs. <styled-content style="fixed-case" toggle="no">HC</styled-content>: heavy chain, <styled-content style="fixed-case" toggle="no">LC</styled-content>: light chain, (<styled-content style="fixed-case" toggle="no">HL</styled-content>)<sub>2</sub>: assembled <styled-content style="fixed-case" toggle="no">mA</styled-content>b with two light and heavy chains.</p></caption><graphic id="nlm-graphic-1" xlink:href="PBI-18-266-g001"/></fig></sec><sec id="pbi13194-sec-0004"><title>Purification of CHKVmab from <italic>N.&#x000a0;benthamiana</italic> leaves</title><p>We have previously developed a two&#x02010;step extraction and purification process consisting of low pH precipitation and protein A chromatography for mAbs produced in plants (Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0025" ref-type="ref">2010</xref>, <xref rid="pbi13194-bib-0026" ref-type="ref">2012</xref>). Using this method, CHKVmab was purified from <italic>N.&#x000a0;benthamiana</italic> leaves to &#x0003e;90% homogeneity (Figure&#x000a0;<xref rid="pbi13194-fig-0002" ref-type="fig">2</xref>). Purified mAbs were used for further biochemical and functional analyses.</p><fig fig-type="Figure" xml:lang="en" id="pbi13194-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Purification of <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab from <italic>Nicotiana benthamiana</italic> leaves. Total soluble proteins were extracted from plants, and <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab was purified and analysed on a 4%&#x02013;20% gradient <styled-content style="fixed-case" toggle="no">SDS</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">PAGE</styled-content> gel under reducing (Lanes 1&#x02013;4) or non&#x02010;reducing (Lanes 5 and 6) conditions and visualized with Coomassie stain. Lane 1, protein molecular weight marker; Lane 2, leaf soluble proteins after low <styled-content style="fixed-case" toggle="no">pH</styled-content> precipitation; Lanes 3 and 5, <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab purified from leaves; Lanes 4 and 6, mammalian cell&#x02010;produced anti&#x02010;<styled-content style="fixed-case" toggle="no">WNV</styled-content> E16 <styled-content style="fixed-case" toggle="no">mA</styled-content>b as a reference standard. <styled-content style="fixed-case" toggle="no">HC</styled-content>: heavy chain, <styled-content style="fixed-case" toggle="no">LC</styled-content>: light chain, (<styled-content style="fixed-case" toggle="no">HL</styled-content>)<sub>2</sub>: assembled <styled-content style="fixed-case" toggle="no">mA</styled-content>b with two light and heavy chains. One representative of several independent experiments is shown.</p></caption><graphic id="nlm-graphic-3" xlink:href="PBI-18-266-g002"/></fig></sec><sec id="pbi13194-sec-0005"><title>N&#x02010;linked glycosylation profiles of plant&#x02010;produced CHKVmabs</title><p>Since the structure of N&#x02010;glycans in the Fc region of an antibody affects its Fc&#x02010;mediated effector functions (Jefferis, <xref rid="pbi13194-bib-0021" ref-type="ref">2012</xref>), the N&#x02010;glycosylation of pCHKVmabs was determined by liquid chromatography&#x02013;electrospray ionization&#x02013;mass spectrometry (LC&#x02010;ESI&#x02010;MS). pCHKVmab produced in &#x02206;XFT plants exhibited the expected mammalian&#x02010;type GnGn N&#x02010;glycan structure lacking plant&#x02010;specific xylose and fucose with a high degree of uniformity (&#x0003e;95%) (Table&#x000a0;<xref rid="pbi13194-tbl-0001" ref-type="table">1</xref>). Glycosylation pattern of WTpCHKVmab was found to carry a mixture of N&#x02010;glycans (Table&#x000a0;<xref rid="pbi13194-tbl-0001" ref-type="table">1</xref>): the major form was as the expected plant typical GnGnXF<sub>3</sub> structure (33%), accompanied by incompletely processed complex N&#x02010;glycans (39%) and oligomannosidic structures (28%).</p><table-wrap id="pbi13194-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>N&#x02010;linked glycans of CHKV mAb variants</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Sample</th><th align="left" valign="top" rowspan="1" colspan="1">GnGnXF<sub>3</sub>
</th><th align="left" valign="top" rowspan="1" colspan="1">GnGnX</th><th align="left" valign="top" rowspan="1" colspan="1">GnMXF<sub>3</sub>
</th><th align="left" valign="top" rowspan="1" colspan="1">GnGn</th><th align="left" valign="top" rowspan="1" colspan="1">Man<sub>(8&#x02010;9)</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x00394;XFpCHKV</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">&#x0003e;95</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">WTpCHKV</td><td align="char" char="." rowspan="1" colspan="1">33</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">28</td></tr></tbody></table><table-wrap-foot id="pbi13194-ntgp-0001"><fn id="pbi13194-note-0001"><p>N&#x02010;glycosylation profile as determined by liquid chromatography&#x02013;electrospray ionization&#x02013;mass spectrometry (LS&#x02010;ESI&#x02010;MS). Numbers represent the presence of various glycoforms in percentage. Note &#x02206;XFT is a <italic>Nicotiana benthamiana</italic> N&#x02010;glycosylation mutant that lacks plant&#x02010;specific core xylose and fucose. Glycans were annotated according to the ProGlycAn nomenclature (<ext-link ext-link-type="uri" xlink:href="http://www.proglycan.com">http://www.proglycan.com</ext-link>).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="pbi13194-sec-0006"><title>Neutralization activity of plant&#x02010;derived CHKVmab against CHIKV</title><p>Plaque reduction neutralization test (PRNT) was used to evaluate the neutralization potential of plant&#x02010;produced mAbs against CHIKV (Yang <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0047" ref-type="ref">2017b</xref>). While the negative control mAb (an anti&#x02010;WNV mAb) did not neutralize CHIKV, both WTpCHKVmab and &#x02206;XFpCHKVmab showed strong neutralizing activity against CHIKV with statistically similar potency (&#x02206;XFpCHKVmab EC<sub>50&#x000a0;</sub>=&#x000a0;130.5&#x000a0;ng/mL vs. WTpCHKVmab EC<sub>50&#x000a0;</sub>=&#x000a0;390.8&#x000a0;ng/mL; <italic>P</italic>&#x000a0;=&#x000a0;0.33) (Figure&#x000a0;<xref rid="pbi13194-fig-0003" ref-type="fig">3</xref>). The mean EC<sub>50</sub> values of plant&#x02010;derived CHKVmabs are comparable to those of mammalian cell&#x02010;produced orthologue (mCHKVmab EC<sub>50</sub>&#x000a0;=&#x000a0;154&#x000a0;ng/mL) (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>). Overall, WTpCHKVmab and &#x02206;XFpCHKVmab exhibited potent neutralizing activity <italic>in vitro</italic> against infectious CHIKV.</p><fig fig-type="Figure" xml:lang="en" id="pbi13194-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The neutralizing activity of <styled-content style="fixed-case" toggle="no">WT</styled-content>p<styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab and &#x02206;<styled-content style="fixed-case" toggle="no">XF</styled-content>p<styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab. Dilutions of <styled-content style="fixed-case" toggle="no">WT</styled-content>p<styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab, &#x02206;<styled-content style="fixed-case" toggle="no">XF</styled-content>p<styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab or a &#x02206;<styled-content style="fixed-case" toggle="no">XF</styled-content> plant&#x02010;produced anti&#x02010;<styled-content style="fixed-case" toggle="no">WNV</styled-content> E16 <styled-content style="fixed-case" toggle="no">mA</styled-content>b (&#x02206;<styled-content style="fixed-case" toggle="no">XF</styled-content>p<styled-content style="fixed-case" toggle="no">WNV</styled-content>mab, negative control) were co&#x02010;incubated with 100 <styled-content style="fixed-case" toggle="no">PFU</styled-content> of <styled-content style="fixed-case" toggle="no">CHIKV</styled-content> and Vero cells for 3&#x000a0;days. Plaques were counted, and per cent neutralization and <styled-content style="fixed-case" toggle="no">EC</styled-content>
<sub>50</sub> were calculated. Experiments were performed twice with technical triplicates for each sample. Bars represent the standard deviation (<styled-content style="fixed-case" toggle="no">SD</styled-content>) of the mean.</p></caption><graphic id="nlm-graphic-5" xlink:href="PBI-18-266-g003"/></fig></sec><sec id="pbi13194-sec-0007"><title>
<italic>In vivo</italic> efficacy of plant&#x02010;derived CHKVmab against CHIKV infection</title><p>Among mouse models of CHIKV infection, WT mice (i.e. WT C57BL/6) develop arthritis symptoms similar to those observed in humans (Broeckel <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0004" ref-type="ref">2017</xref>). Thus, we used the WT C57BL/6 mouse model to assess the <italic>in vivo</italic> therapeutic efficacy of plant&#x02010;produced CHKVmabs (Acharya <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0001" ref-type="ref">2015</xref>). Five&#x02010;week&#x02010;old C57BL/6 mice were inoculated in the right footpad with 1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> PFU of CHIKV and then treated at 12&#x000a0;h post&#x02010;infection with 50&#x000a0;&#x003bc;g of WTpCHKVmab, &#x02206;XFpCHKVmab or PBS intraperitoneally. Since viraemia generally peaks at 2&#x000a0;dpi and subsides to undetectable levels at 4&#x000a0;dpi in this mouse model, blood was collected at 2&#x000a0;dpi and viraemia measured by RT&#x02010;qPCR. Mice treated with both WTpCHKVmab and &#x02206;XFpCHKVmab developed significantly lower viraemia compared to PBS&#x02010;treated mice (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 for WTpCHKVmab; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01 for &#x02206;XFpCHKVmab) (Figure&#x000a0;<xref rid="pbi13194-fig-0004" ref-type="fig">4</xref>). Interestingly, &#x02206;XFpCHKVmab appeared to be more potent than WTpCHKVmab in reducing viral load in mice (Figure&#x000a0;<xref rid="pbi13194-fig-0004" ref-type="fig">4</xref>). Statistical analysis indicated that albeit not dramatic, the difference in efficacy between the two mAb glycovariants was nonetheless significant (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, &#x02206;XFpCHKVmab compared to WTpCHKVmab). Collectively, the <italic>in vivo</italic> efficacy of plant&#x02010;derived CHKVmabs in WT mice suggests their potential as prophylaxis and post&#x02010;exposure therapeutics for CHIKV.</p><fig fig-type="Figure" xml:lang="en" id="pbi13194-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Plant&#x02010;produced <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mabs reduce <styled-content style="fixed-case" toggle="no">CHIKV</styled-content> viraemia in mice. Wild&#x02010;type C57<styled-content style="fixed-case" toggle="no">BL</styled-content>/6J mice (<italic>N</italic>&#x000a0;=&#x000a0;6 per group) were subcutaneously infected with 1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup>&#x000a0;<styled-content style="fixed-case" toggle="no">PFU</styled-content>s of <styled-content style="fixed-case" toggle="no">CHIKV</styled-content> and treated intraperitoneally with 50&#x000a0;&#x003bc;g of indicated <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab or <styled-content style="fixed-case" toggle="no">PBS</styled-content> (negative control) 12&#x000a0;h post&#x02010;infection. Viral load in blood at day 2&#x000a0;dpi is presented as a ratio of <styled-content style="fixed-case" toggle="no">CHIKV</styled-content>&#x000a0;E1&#x000a0;copy number per 1000 copy of cellular&#x000a0;&#x003b2;&#x02010;actin. ** and * indicate <italic>P</italic> values &#x0003c;0.01 and &#x0003c;0.05, respectively, of <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mab&#x02010;treated mice compared to that of <styled-content style="fixed-case" toggle="no">PBS</styled-content>&#x02010;treated, which were determined by <italic>t</italic>&#x02010;tests.</p></caption><graphic id="nlm-graphic-7" xlink:href="PBI-18-266-g004"/></fig></sec><sec id="pbi13194-sec-0008"><title>Antibody&#x02010;dependent enhancement activity of plant&#x02010;produced CHKVmab for DENV infection</title><p>One of the challenges for mAb therapeutics against viral infections is the increased risk of infection by other viruses in treated patients via the mechanism of antibody&#x02010;dependent enhancement of infection (ADE). For example, cross&#x02010;reactive but sub&#x02010;neutralizing antibodies against one serotype of DENV from a previous infection can form complexes with another serotype of DENV during a secondary infection to promote viral infection of Fc&#x003b3;R&#x02010;bearing myeloid cells, predisposing patients to develop the more severe dengue haemorrhagic fever/dengue shock syndrome through ADE (Sun <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0042" ref-type="ref">2018</xref>). Since the E proteins of CHIKV and DENV are related and the two viruses co&#x02010;circulate geographically (Kam <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0023" ref-type="ref">2015</xref>), we examined whether CHKVmab would enhance the infection of DENV. As previously demonstrated (Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0028" ref-type="ref">2018</xref>), 4G2, an mAb that cross&#x02010;reacts with E of most flaviviruses, efficiently caused ADE of DENV infection in K562 cells that express the human Fc&#x003b3;R (Figure&#x000a0;<xref rid="pbi13194-fig-0005" ref-type="fig">5</xref>). In contrast, &#x02206;XFpCHKVmab and WTpCHKVmab did not promote ADE for DENV (Figure&#x000a0;<xref rid="pbi13194-fig-0005" ref-type="fig">5</xref>). These results indicate that plant&#x02010;produced CHKVmabs are not only efficacious but also safe as potential treatment against CHIKV infection.</p><fig fig-type="Figure" xml:lang="en" id="pbi13194-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Antibody&#x02010;dependent enhancement of <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mabs for <styled-content style="fixed-case" toggle="no">DENV</styled-content> infection. Serial dilutions of <styled-content style="fixed-case" toggle="no">CHKV</styled-content>mabs or 4G2 (positive control <styled-content style="fixed-case" toggle="no">mA</styled-content>b) were mixed with <styled-content style="fixed-case" toggle="no">DENV</styled-content>&#x02010;2 and then incubated with Fc&#x003b3;<styled-content style="fixed-case" toggle="no">RII</styled-content>a<sup>+</sup> K562 cells. Cells were fixed, permeabilized and stained with an anti&#x02010;<styled-content style="fixed-case" toggle="no">DENV</styled-content> E antibody and analysed by flow cytometry.</p></caption><graphic id="nlm-graphic-9" xlink:href="PBI-18-266-g005"/></fig></sec></sec><sec sec-type="discussion" id="pbi13194-sec-0009"><title>Discussion</title><p>The expanding epidemics of CHIKV demand the development of efficacious therapeutics against this debilitating virus. A screening of 230 mouse anti&#x02010;CHIKV mAbs indicate that some of the antibodies against CHIKV E1 and E2 have protective activity and their protectivity is mostly correlated to the neutralizing potency (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>). Furthermore, antibody Fc effector functions have been found to be crucial for the efficacy of these anti&#x02010;CHIKV antibodies (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>). In the current study, we explored the feasibility of using plant&#x02010;produced mAbs against E1 in treating CHIKV infection in a mouse model as a step towards improving the efficacy of CHIKV immunotherapy in humans.</p><p>A prerequisite for plant&#x02010;made mAbs to be competitive alternatives of those made in mammalian cells is their robust production in plants. While mAb production in mammalian cell culture is highly efficient, production costs are immense ($80&#x000a0;000&#x02013;160&#x000a0;000/kg protein; Shevitz <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0039" ref-type="ref">2011</xref>) and, in many cases, unaffordable to people in many parts of the world. In contrast, production of plant&#x02010;derived proteins does not require expensive cell&#x02010;culture facilities, bioreactors, or tissue culture media and production can be scaled up for commercial manufacture without prohibitive capital investments (Chen and Davis, <xref rid="pbi13194-bib-0007" ref-type="ref">2016</xref>; Tuse <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0043" ref-type="ref">2014</xref>). Indeed, recent case studies have confirmed that <italic>N.&#x000a0;benthamiana</italic>&#x02010;based platforms can substantially reduce the upstream production cost of biologics to as low as $1.00&#x02013;2.00 per kilogram of protein (Tuse <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0043" ref-type="ref">2014</xref>). Our results indicated that both WTpCHKVmab and &#x02206;XFpCHKVmab accumulated in <italic>N.&#x000a0;benthamiana</italic> leaves to levels comparable to other mAbs produced in plants with non&#x02010;optimized codons (Chen and Lai, <xref rid="pbi13194-bib-0009" ref-type="ref">2014b</xref>). Under optimized conditions, however, mAbs can be produced up to 0.8&#x02013;4.8&#x000a0;mg/g LFW, a commercially feasible level for mAb manufacturing (Bendandi <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0003" ref-type="ref">2010</xref>; Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0025" ref-type="ref">2010</xref>). Our results also showed that WTpCHKVmab and &#x02206;XFpCHKVmab were readily extracted and purified from leaves with a scalable process that is compliant to current Good Manufacturing Practice (cGMP) regulations (Lai and Chen, <xref rid="pbi13194-bib-0024" ref-type="ref">2012</xref>; Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0025" ref-type="ref">2010</xref>). In fact, biotechnology companies, such as Fraunhofer IME, already have a cGMP manufacturing licence for plant&#x02010;produced mAbs (Ma <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0031" ref-type="ref">2015</xref>) and can easily adopt the downstream process we developed here for the future manufacturing of CHKVmabs. Together, these results indicate that similar to CHIKV vaccine development (Cardona&#x02010;Ospina <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0005" ref-type="ref">2016</xref>; Salazar&#x02010;Gonzalez <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0037" ref-type="ref">2015</xref>), the <italic>N.&#x000a0;benthamiana</italic>&#x02010;based plant system has the potential to produce anti&#x02010;CHIKV mAbs with favourable yield and cost, which will markedly increase the affordability of mAb&#x02010;based CHIKV drugs to people in the developing world, where the majority of CHIKV cases occurs.</p><p>Another striking feature of the plant transient expression platform is the rapid production for an identified target. This is particularly important in cases of sudden disease outbreaks and the subsequent urgent need of therapeutics for immediate use, a typical scenario of viral outbreaks. In the plant transient system, a time frame of 1&#x02013;2&#x000a0;weeks is sufficient for the generation of 1&#x000a0;g of product per kg of leaves after gene construct delivery (Lomonossoff and D'Aoust, <xref rid="pbi13194-bib-0030" ref-type="ref">2016</xref>). Based on our data and information available from ZMapp large&#x02010;scale production (Arntzen, <xref rid="pbi13194-bib-0002" ref-type="ref">2015</xref>; Holtz <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0019" ref-type="ref">2015</xref>; Lai and Chen, <xref rid="pbi13194-bib-0024" ref-type="ref">2012</xref>; Zeitlin and Haydon, <xref rid="pbi13194-bib-0050" ref-type="ref">2015</xref>), we estimate that a current U.S.&#x02010;based contract manufacturing facility (CMO) can generate leaves containing 1&#x000a0;kg of CHKVmab within 2&#x000a0;weeks from the delivery of the expression vectors described in this study. At this moment, this production speed cannot be matched by any other expression system and our work may contribute to rapidly producing pharmaceuticals to combat emerging diseases.</p><p>To be considered as therapeutic candidates, plant&#x02010;made mAbs must have at least equivalent potency as their mammalian cell&#x02010;produced counterparts. A major mechanism of antiviral activity for anti&#x02010;CHIKV mAbs is viral neutralization (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>). Plant&#x02010;made CHKVmab exhibited strong neutralizing activity against CHIKV with potencies similar to mammalian cell&#x02010;derived CHKVmab (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>). Importantly, <italic>in vitro</italic> activities of plant&#x02010;made CHKVmabs translated to <italic>in vivo</italic> efficacy. There are several mouse models for evaluating the protectivity of mAbs against CHIKV. Immune compromised (Ifnar &#x02010;/&#x02010; or AG129) mice are subject to lethal CHIKV infection, providing a convenient survival model (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>). However, these mice do not develop the arthritis observed in humans. In contrast, CHIKV infection in WT C57BL/6 mice causes arthritis and swelling in feet and ankles (Broeckel <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0004" ref-type="ref">2017</xref>), presenting a more relevant animal model for studying human CHIKV infection. CHIKV infection in WT C57BL/6 mice does not cause lethal infection, but a transient viraemia &#x02013; detectable at 1&#x000a0;dpi, reaching its peak at 2&#x000a0;dpi and subsiding by 4&#x000a0;dpi (Acharya <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0001" ref-type="ref">2015</xref>). In this relevant model, we observed that pCHKVmabs significantly reduced titres of virus in blood at 2&#x000a0;dpi, demonstrating the potential of plant&#x02010;produced mAbs as efficacious post&#x02010;exposure therapeutics <italic>in vivo</italic>.</p><p>One of the advantages of using plant&#x02010;based platforms to produce antibodies is the ability to alter N&#x02010;glycans present on the single glycosylation site at the Fc domain (Strasser <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0041" ref-type="ref">2014</xref>). IgG Fc effector functions depend on the specific interaction between the IgG Fc domain and Fc&#x003b3;R on immune cells which, in turn, is highly sensitive to the composition of N&#x02010;linked Fc glycans (Jefferis, <xref rid="pbi13194-bib-0021" ref-type="ref">2012</xref>). MAbs produced in mammalian cells usually carry a mixture of N&#x02010;glycans, with some glycoforms being more bioactive than others (Jefferis, <xref rid="pbi13194-bib-0020" ref-type="ref">2005</xref>). As such, glycoengineered plant lines that produce mAbs with distinct N&#x02010;glycans are highly appreciated for optimizing the therapeutic potency of mAbs, especially for those that require Fc effector function for efficacy. For example, glycoengineered plants have been used to increase the efficacy of anti&#x02010;filovirus and anti&#x02010;HIV antibodies (Forthal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0013" ref-type="ref">2010</xref>; Zeitlin <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0051" ref-type="ref">2011</xref>). Moreover, our laboratory has demonstrated that anti&#x02010;DENV antibodies produced in &#x02206;XFT and WT <italic>N.&#x000a0;benthamiana</italic> plants forgo their ADE activity and, consequently, have superior efficacy and safety profiles than their mammalian&#x02010;produced counterparts most likely due to their specific N&#x02010;glycosylation profile (Dent <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0012" ref-type="ref">2016</xref>). Since anti&#x02010;CHIKV E1 and E2 mAbs require Fc effector function for their efficacy (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>), their activities may be optimized by modulating glycosylation profiles. Indeed, our results showed that &#x02206;XFpCHKVmab had better <italic>in vivo</italic> efficacy against CHIKV than WTpCHKVmab. These results support our hypothesis that some antibody glycoforms may have superior protectivity than others by enhancing antibody's effector functions. We believe that the difference in potency between &#x02206;XFpCHKVmab and WTpCHKVmab can be much greater if they both carry a homogenous glycoform. These results warrant further studies with additional anti&#x02010;CHIKV mAbs using multiple glycoengineered plant lines (Chen, <xref rid="pbi13194-bib-0006" ref-type="ref">2016</xref>; Montero&#x02010;Morales and Steinkellner, <xref rid="pbi13194-bib-0033" ref-type="ref">2018</xref>).</p><p>Collectively, we demonstrate the efficient expression, purification and the potent efficacy of two glycoforms of an anti&#x02010;CHIKV E1 mAb in plants and show that their <italic>in vivo</italic> potency may be optimized by the attachment of defined glycan profiles. In addition, neither of the two mAb glycoforms promoted ADE for DENV infection. These results suggest that mAbs have the potential to be used as effective and safe prophylaxis to prevent CHIKV infection during outbreaks, especially for populations with high risk of developing severe diseases. To our knowledge, this is the first report of the efficacy of plant&#x02010;produced mAbs against CHIKV. Our results warrant future studies in mouse arthritis models that mimic symptoms of human CHIKV infection. In the context of recent studies that demonstrate broadly neutralizing human mAbs against CHIKV E2 with therapeutic activity (Smith <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0040" ref-type="ref">2015</xref>), our work can be expanded to the development of a novel multi&#x02010;target therapy to combat sudden CHIKV outbreaks.</p></sec><sec sec-type="materials-and-methods" id="pbi13194-sec-0010"><title>Materials and methods</title><sec id="pbi13194-sec-0011"><title>Ethics statement and biosafety</title><p>All animal experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committees (IACUC) at the University of Southern Mississippi (USM). All&#x000a0;<italic>in vitro</italic> experiments and animal studies involving live CHIKV were performed by the certified personnel in the USM biosafety level 3 (BSL3) facility by following standard biosafety protocols approved by the USM Institutional Biosafety Committee (IBC).</p></sec><sec id="pbi13194-sec-0012"><title>Vector construction for expression of CHKVmab</title><p>The coding sequence of CHKVmab variable region of HC (V<sub>H</sub>) and LC (V<sub>L</sub>) (Pal <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0034" ref-type="ref">2013</xref>) was fused to the corresponding DNA sequences of human IgG1 constant regions of HC (C<sub>H</sub>) and LC (C<sub>L</sub>), respectively. The resulting HC and LC coding sequences were cloned into MagnICON&#x02010;based plant expression vectors pICH21595 and pICH11599, and transformed into <italic>A.&#x000a0;tumefaciens</italic> as described previously (He <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0016" ref-type="ref">2012</xref>; Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0025" ref-type="ref">2010</xref>).</p></sec><sec id="pbi13194-sec-0013"><title>Transient expression of pCHKVmab in <italic>N.&#x000a0;benthamiana</italic> leaves</title><p>Wild&#x02010;type and &#x02206;XFT <italic>N.&#x000a0;benthamiana</italic> plants were grown and agroinfiltrated with <italic>A.&#x000a0;tumefaciens</italic> strains that contain CHKVmab HC and LC 3&#x02032; modules along with their respective 5&#x02032; modules, and an integrase construct as described previously (Chen <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0010" ref-type="ref">2013</xref>; Leuzinger <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0029" ref-type="ref">2013</xref>).</p></sec><sec id="pbi13194-sec-0014"><title>Extraction and purification of pCHKVmab from plants</title><p>Agroinfiltrated leaves were harvested 7&#x000a0;dpi, and CHKVmab was extracted and purified with a method previously developed for anti&#x02010;WNV and DENV mAbs (Dent <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0012" ref-type="ref">2016</xref>; Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0025" ref-type="ref">2010</xref>, <xref rid="pbi13194-bib-0026" ref-type="ref">2012</xref>). Briefly, the crude leaf extract was obtained by homogenization in extraction buffer (1&#x000a0;&#x000d7;&#x000a0;PBS pH 5.2, 10&#x000a0;mg/mL sodium ascorbate, 1&#x000a0;m<sc>m</sc> EDTA) and clarified by centrifugation at 15&#x000a0;000&#x000a0;<italic><bold>g</bold></italic> for 30&#x000a0;min at 4&#x000a0;&#x000b0;C. CHKVmab in clarified protein extract was purified by a two&#x02010;step purification process comprised of low pH precipitation followed by protein A affinity chromatography.</p></sec><sec id="pbi13194-sec-0015"><title>Protein analyses</title><p>SDS&#x02010;PAGE (10% or 4%&#x02013;20% gradient) was performed either under reducing (5% v/v &#x003b2;&#x02010;mercaptoethanol) or non&#x02010;reducing conditions. SDS&#x02010;PAGE gels were stained with Coomassie blue. For Western blot analysis, proteins on SDS&#x02010;PAGE gels were transferred onto PVDF membranes and detected with horseradish peroxidase (HRP)&#x02010;conjugated antibodies against human kappa LC or gamma HC (Southern Biotech, Birmingham, AL) as previously described (Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0027" ref-type="ref">2014</xref>).</p><p>The expression level of CHKVmab was measured by an ELISA that detected the fully assembled form of mAbs with both HC and LC (Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0025" ref-type="ref">2010</xref>). Briefly, plates were coated with an anti&#x02010;human gamma HC antibody (Southern Biotech) and incubated with the plant protein extract. After washing, a HRP&#x02010;conjugated anti&#x02010;human kappa LC antibody (Southern Biotech) was used for detection. A plant&#x02010;produced mAb with human IgG1 CH and kappa CL (E16) (Lai <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0025" ref-type="ref">2010</xref>) was used as a reference standard.</p></sec><sec id="pbi13194-sec-0016"><title>N&#x02010;linked glycan analysis</title><p>LC&#x02010;ESI&#x02010;MS was used to determine the N&#x02010;linked glycosylation profiles of CHKVmab variants as previously reported (Dent <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0012" ref-type="ref">2016</xref>). Briefly, the HC band of purified CHKVmabs on Coomassie&#x02010;stained SDS&#x02010;PAGE was excised from the gel. Peptide fragments were generated by S&#x02010;alkylation and tryptic or tryptic/GluC digestion and subsequently eluted from the gel with 50% acetonitrile. Peptide fragments were then separated on a Reversed&#x02010;Phase Column (150&#x000a0;&#x000d7;&#x000a0;0.32&#x000a0;mm BioBasic 18, Thermo Fisher Scientific) with a 1%&#x02013;80% acetonitrile gradient. Glycopeptides were analysed with a quadruple time&#x02010;of&#x02010;flight (Q&#x02010;TOF) Ultima Global mass spectrometer (Waters, Milford, MA). Spectra were summed and deconvoluted for identification of glycoforms. The ProGlycAn nomenclature (<ext-link ext-link-type="uri" xlink:href="http://www.proglycan.com">http://www.proglycan.com</ext-link>) was used to annotate the glycans.</p></sec><sec id="pbi13194-sec-0017"><title>Virus and cells</title><p>CHIKV (strain LR&#x02010;OPY1, kindly provided by Dr. Robert B. Tesh at University of Texas Medical Branch) was propagated and tittered in Vero cells (ATCC, CCL&#x02010;81). Vero cells were cultured in DMEM supplemented with 10% FBS at 37&#x000a0;&#x000b0;C in an incubation with 5% CO<sub>2</sub>.</p></sec><sec id="pbi13194-sec-0018"><title>CHIKV neutralization and plaque assay</title><p>Plaque reduction neutralization test (PRNT) was performed as previously described (Yang <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0046" ref-type="ref">2017a</xref>, <xref rid="pbi13194-bib-0048" ref-type="ref">2018</xref>). Specifically, mAbs were serially diluted in phosphate&#x02010;buffered saline (PBS), while CHIKV was diluted in serum&#x02010;free DMEM to a working concentration of 100 plaque&#x02010;forming units (PFUs) per well. Following dilutions, mAbs were added to CHIKV and incubated for 1&#x000a0;h at 37&#x000a0;&#x000b0;C. CHIKV&#x02010;mAb mixes were then added to a 90%&#x02013;95% confluence Vero cells in a 6&#x02010;well tissue culture plate and incubated for 1&#x000a0;h at 37&#x000a0;&#x000b0;C for virus attachment. After removing unattached virus&#x02010;mAbs in the medium, cells were overlaid with fresh media (complete DMEM containing 1% sea plaque agarose, Lonza) and incubated for an additional 3&#x000a0;days at 37&#x000a0;&#x000b0;C. Plaques were visualized by staining with neutral red (Sigma) and counted. Percent (%) neutralization was calculated as: [(number of CHIKV plaque per well with no mAb) &#x02212; (number of CHIKV plaque per well of diluted mAb)/(number of CHIKV plaque per well with no mAb) &#x000d7; 100]. Experiments were repeated twice. The half maximal effective concentration (EC<sub>50</sub>) of each mAb was calculated using GraphPad Prism software (version 6.0).</p></sec><sec id="pbi13194-sec-0019"><title>Animal studies</title><p>Female C57BL/6J mice (5&#x000a0;weeks old, six mice per group) were purchased from the Jackson Laboratory and subcutaneously inoculated on the ventral side of the right hind footpad with 10<sup>5</sup> PFUs of CHIKV as previously described (Acharya <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0001" ref-type="ref">2015</xref>). Mice were intraperitoneally inoculated with 50&#x000a0;&#x003bc;g of CHKVmabs or PBS at 12&#x000a0;h post&#x02010;CHIKV infection. Mice were bled retro&#x02010;orbitally at 2&#x000a0;dpi to measure viraemia.</p></sec><sec id="pbi13194-sec-0020"><title>Real&#x02010;time quantitative PCR (RT&#x02010;qPCR)</title><p>Total RNA was isolated from mouse blood samples using TRI reagent (Molecular Research Center, Inc.). The first&#x02010;strand complementary DNA (cDNA) was synthesized by using the iSCRIPT cDNA synthesis kit (Bio&#x02010;Rad). CHIKV envelope protein 1 (CHIKV E1) and cellular &#x003b2;&#x02010;actin RNA copy numbers were determined by RT&#x02010;qPCR in a CFX96 Real&#x02010;Time System (Bio&#x02010;Rad) using SYBR Green Supermix (Bio&#x02010;Rad). Viral copy numbers were expressed as the ratio of CHIKV E1 to cellular &#x003b2;&#x02010;actin. Primer sequences for&#x000a0;mouse &#x003b2;&#x02010;actin&#x000a0;and CHIKV&#x000a0;E1&#x000a0;gene were previously described (Acharya <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0001" ref-type="ref">2015</xref>).</p></sec><sec id="pbi13194-sec-0021"><title>Antibody&#x02010;dependent enhancement assay</title><p>The potential enhancing activities of the anti&#x02010;CHIKV mAbs for DENV infection were examined by using Fc&#x003b3;RIIa<sup>+</sup> K562 cells (ATCC, CCL&#x02010;2243) as previously described (Dent <italic>et&#x000a0;al</italic>., <xref rid="pbi13194-bib-0012" ref-type="ref">2016</xref>). Serial dilutions of CHKVmabs or the positive control mAb 4G2 were initially incubated with DENV&#x02010;2 (ATCC, VR&#x02010;1584) for 1&#x000a0;hr at 37&#x000a0;&#x000b0;C. Thereafter, the mAb&#x02013;virus complexes were incubated with K562 cells (MOI&#x000a0;=&#x000a0;1) for 48&#x000a0;h. Cells were then fixed with 4% paraformaldehyde (Sigma), permeabilized with 0.1% saponin (Sigma), and stained with Alexa 488 (Invitrogen)&#x02010;conjugated 4G2 (ATCC, HB112). Stained cells were washed and analysed with a Navios flow cytometer (Beckman Coulter) to determine the percentage of infected cells.</p></sec><sec id="pbi13194-sec-0022"><title>Statistical analyses</title><p>Data analysis was performed using GraphPad Prism software version 6.0 (GraphPad, CA). Comparisons of neutralization potency between different mAbs were performed using <italic>t</italic>&#x02010;tests. Comparison of blood viral copy numbers between mouse groups treated with different mAbs was also performed by <italic>t</italic>&#x02010;tests. A <italic>P</italic> value of &#x0003c;0.05 indicated statistically significant difference.</p></sec></sec><sec id="pbi13194-sec-0023"><title>Author contributions</title><p>Q.C. designed the research; J.H., D.A., H.L., H.S., and S.K. performed the research; J.H., D.A., H.L., H.S., F.B. and Q.C. analysed the data; and Q.C. wrote the paper with H.S. and F.B. providing critical comments.</p></sec></body><back><ack id="pbi13194-sec-0024"><title>Acknowledgements</title><p>The authors wish to thank&#x000a0;Drs. Friedrich Altmann&#x000a0;and Clemens Gruber at University of Natural Resources and Applied Life Sciences for N&#x02010;glycan analyses. The authors also acknowledge Dr. Robert B. Tesh at University of Texas Medical Branch for providing CHIKV strain and Collin Jugler for the critical reading of the manuscript. All authors declare no conflict of interest for the publication of this manuscript. This work was supported in part by grants from National Institute of Allergy and Infectious Diseases (NIAID) # R33AI101329 to QC and # R15A113706 and R15AI135893 to FB.</p></ack><ref-list content-type="cited-references" id="pbi13194-bibl-0001"><title>References</title><ref id="pbi13194-bib-0001"><mixed-citation publication-type="journal" id="pbi13194-cit-0001">
<string-name>
<surname>Acharya</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Paul</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>, <given-names>J.F.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>, <given-names>F.</given-names>
</string-name> and <string-name>
<surname>Bai</surname>, <given-names>F.</given-names>
</string-name> (<year>2015</year>) <article-title>Loss of glycosaminoglycan receptor binding after mosquito cell passage reduces chikungunya virus infectivity</article-title>. <source xml:lang="en">PLoS Negl. Trop Dis.</source>
<volume>9</volume>, <fpage>e0004139</fpage>.<pub-id pub-id-type="pmid">26484530</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0002"><mixed-citation publication-type="journal" id="pbi13194-cit-0002">
<string-name>
<surname>Arntzen</surname>, <given-names>C.</given-names>
</string-name> (<year>2015</year>) <article-title>Plant&#x02010;made pharmaceuticals: from &#x02018;Edible Vaccines&#x02019; to Ebola therapeutics</article-title>. <source xml:lang="en">Plant Biotechnol. J.</source>
<volume>13</volume>, <fpage>1013</fpage>&#x02013;<lpage>1016</lpage>.<pub-id pub-id-type="pmid">26345276</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0003"><mixed-citation publication-type="journal" id="pbi13194-cit-0003">
<string-name>
<surname>Bendandi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Marillonnet</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kandzia</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Thieme</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Nickstadt</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Herz</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Frode</surname>, <given-names>R.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2010</year>) <article-title>Rapid, high&#x02010;yield production in plants of individualized idiotype vaccines for non&#x02010;Hodgkin's lymphoma</article-title>. <source xml:lang="en">Ann. Oncol.</source>
<volume>21</volume>, <fpage>2420</fpage>&#x02013;<lpage>2427</lpage>.<pub-id pub-id-type="pmid">20494963</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0004"><mixed-citation publication-type="journal" id="pbi13194-cit-0004">
<string-name>
<surname>Broeckel</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Fox</surname>, <given-names>J.M.</given-names>
</string-name>, <string-name>
<surname>Haese</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Kreklywich</surname>, <given-names>C.N.</given-names>
</string-name>, <string-name>
<surname>Sukulpovi&#x02010;Petty</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Legasse</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>, <given-names>P.P.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2017</year>) <article-title>Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques</article-title>. <source xml:lang="en">PLoS Negl. Trop Dis.</source>
<volume>11</volume>, <fpage>e0005637</fpage>.<pub-id pub-id-type="pmid">28628616</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0005"><mixed-citation publication-type="journal" id="pbi13194-cit-0005">
<string-name>
<surname>Cardona&#x02010;Ospina</surname>, <given-names>J.A.</given-names>
</string-name>, <string-name>
<surname>Sepulveda&#x02010;Arias</surname>, <given-names>J.C.</given-names>
</string-name>, <string-name>
<surname>Mancilla</surname>, <given-names>L.</given-names>
</string-name> and <string-name>
<surname>Gutierrez&#x02010;Lopez</surname>, <given-names>L.G.</given-names>
</string-name> (<year>2016</year>) <article-title>Plant expression systems, a budding way to confront chikungunya and Zika in developing countries?</article-title>
<source xml:lang="en">F1000Res</source>, <volume>5</volume>, <fpage>2121</fpage>.<pub-id pub-id-type="pmid">27781090</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0006"><mixed-citation publication-type="journal" id="pbi13194-cit-0006">
<string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> (<year>2016</year>) <article-title>Glycoengineering of plants yields glycoproteins with polysialylation and other defined N&#x02010;glycoforms</article-title>. <source xml:lang="en">Proc. Natl Acad. Sci.</source>
<volume>113</volume>, <fpage>9404</fpage>&#x02013;<lpage>9406</lpage>.<pub-id pub-id-type="pmid">27506788</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0007"><mixed-citation publication-type="journal" id="pbi13194-cit-0007">
<string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> and <string-name>
<surname>Davis</surname>, <given-names>K.</given-names>
</string-name> (<year>2016</year>) <article-title>The potential of plants as a system for the development and production of human biologics</article-title>. <source xml:lang="en">F1000Res</source>, <volume>5</volume>, <fpage>pii: F1000</fpage>.</mixed-citation></ref><ref id="pbi13194-bib-0008"><mixed-citation publication-type="journal" id="pbi13194-cit-0008">
<string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> and <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name> (<year>2014a</year>) <article-title>Gene delivery into plant cells for recombinant protein production</article-title>. <source xml:lang="en">Biomed. Res. Int.</source>
<volume>2014</volume>, <fpage>10</fpage>.</mixed-citation></ref><ref id="pbi13194-bib-0009"><mixed-citation publication-type="book" id="pbi13194-cit-0009">
<string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> and <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name> (<year>2014b</year>) <chapter-title>Plant&#x02010;derived monoclonal antibodies as human biologics for infectious disease and cancer</chapter-title> In <source xml:lang="en">Plant&#x02010;derived Pharmaceuticals: Principles and Applications for Developing Countries</source>(<person-group person-group-type="editor"><name name-style="western"><surname>Hefferon</surname><given-names>K.L.</given-names></name></person-group>, ed), pp. <fpage>42</fpage>&#x02013;<lpage>75</lpage>. <publisher-loc>Croydon, UK</publisher-loc>: <publisher-name>CABI</publisher-name>.</mixed-citation></ref><ref id="pbi13194-bib-0010"><mixed-citation publication-type="journal" id="pbi13194-cit-0010">
<string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Hurtado</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Stahnke</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Leuzinger</surname>, <given-names>K.</given-names>
</string-name> and <string-name>
<surname>Dent</surname>, <given-names>M.</given-names>
</string-name> (<year>2013</year>) <article-title>Agroinfiltration as an effective and scalable strategy of gene delivery for production of pharmaceutical proteins</article-title>. <source xml:lang="en">Adv. Technol. Biol. Med.</source>
<volume>1</volume>, <fpage>103</fpage>&#x02013;<lpage>112</lpage>.</mixed-citation></ref><ref id="pbi13194-bib-0011"><mixed-citation publication-type="journal" id="pbi13194-cit-0011">
<string-name>
<surname>De Muynck</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Navarre</surname>, <given-names>C.</given-names>
</string-name> and <string-name>
<surname>Boutry</surname>, <given-names>M.</given-names>
</string-name> (<year>2010</year>) <article-title>Production of antibodies in plants: status after twenty years</article-title>. <source xml:lang="en">Plant Biotechnol. J.</source>
<volume>8</volume>, <fpage>529</fpage>&#x02013;<lpage>563</lpage>.<pub-id pub-id-type="pmid">20132515</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0012"><mixed-citation publication-type="journal" id="pbi13194-cit-0012">
<string-name>
<surname>Dent</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hurtado</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Paul</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Esqueda</surname>, <given-names>A.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2016</year>) <article-title>Plant&#x02010;produced anti&#x02010;dengue virus monoclonal antibodies exhibit reduced antibody&#x02010;dependent enhancement of infection activity</article-title>. <source xml:lang="en">J. Gen. Virol.</source>
<volume>97</volume>, <fpage>3280</fpage>&#x02013;<lpage>3290</lpage>.<pub-id pub-id-type="pmid">27902333</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0013"><mixed-citation publication-type="journal" id="pbi13194-cit-0013">
<string-name>
<surname>Forthal</surname>, <given-names>D.N.</given-names>
</string-name>, <string-name>
<surname>Gach</surname>, <given-names>J.S.</given-names>
</string-name>, <string-name>
<surname>Landucci</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Jez</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Strasser</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Kunert</surname>, <given-names>R.</given-names>
</string-name> and <string-name>
<surname>Steinkellner</surname>, <given-names>H.</given-names>
</string-name>.(<year>2010</year>) <article-title>Fc-Glycosylation Influences Fc&#x003b3; Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12</article-title>. <source xml:lang="en">The Journal of Immunology.</source>
<volume>185</volume>, <fpage>6876</fpage>&#x02013;<lpage>6882</lpage>.<pub-id pub-id-type="pmid">21041724</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0014"><mixed-citation publication-type="journal" id="pbi13194-cit-0014">
<string-name>
<surname>Garber</surname>, <given-names>K.</given-names>
</string-name>.(<year>2018</year>) <article-title>No added sugar: antibody makers find an upside to 'no fucose'</article-title>. <source xml:lang="en">Nature Biotechnology</source>
<volume>36</volume>, <fpage>1025</fpage>&#x02013;<lpage>1027</lpage>.</mixed-citation></ref><ref id="pbi13194-bib-0015"><mixed-citation publication-type="journal" id="pbi13194-cit-0015">
<string-name>
<surname>Giritch</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Marillonnet</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Engler</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>van Eldik</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Botterman</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Klimyuk</surname>, <given-names>V.</given-names>
</string-name> and <string-name>
<surname>Gleba</surname>, <given-names>Y.</given-names>
</string-name> (<year>2006</year>) <article-title>Rapid high&#x02010;yield expression of full&#x02010;size IgG antibodies in plants coinfected with noncompeting viral vectors</article-title>. <source xml:lang="en">Proc. Natl. Acad. Sci. USA</source>, <volume>103</volume>, <fpage>14701</fpage>&#x02013;<lpage>14706</lpage>.<pub-id pub-id-type="pmid">16973752</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0016"><mixed-citation publication-type="journal" id="pbi13194-cit-0016">
<string-name>
<surname>He</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Brock</surname>, <given-names>C.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> (<year>2012</year>) <article-title>A novel system for rapid and cost&#x02010;effective production of detection and diagnostic reagents of west Nile virus in plants</article-title>. <source xml:lang="en">J. Biomed. Biotechnol.</source>
<volume>2012</volume>, <fpage>1</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">21836813</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0017"><mixed-citation publication-type="journal" id="pbi13194-cit-0017">
<string-name>
<surname>He</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Engle</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Gorlatov</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gruber</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Steinkellner</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Diamond</surname>, <given-names>M.S.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2014</year>) <article-title>Generation and analysis of novel plant&#x02010;derived antibody&#x02010;based therapeutic molecules against west nile virus</article-title>. <source xml:lang="en">PLoS ONE</source>, <volume>9</volume>, <fpage>e93541</fpage>.<pub-id pub-id-type="pmid">24675995</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0018"><mixed-citation publication-type="journal" id="pbi13194-cit-0018">
<string-name>
<surname>Hiatt</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bohorova</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Bohorov</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Pauly</surname>, <given-names>M.H.</given-names>
</string-name>, <string-name>
<surname>Velasco</surname>, <given-names>J.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2014</year>) <article-title>Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and <italic>in vivo</italic> efficacy</article-title>. <source xml:lang="en">Proc. Natl Acad. Sci.</source>
<volume>111</volume>, <fpage>5992</fpage>&#x02013;<lpage>5997</lpage>.<pub-id pub-id-type="pmid">24711420</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0019"><mixed-citation publication-type="journal" id="pbi13194-cit-0019">
<string-name>
<surname>Holtz</surname>, <given-names>B.R.</given-names>
</string-name>, <string-name>
<surname>Berquist</surname>, <given-names>B.R.</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>, <given-names>L.D.</given-names>
</string-name>, <string-name>
<surname>Kommineni</surname>, <given-names>V.J.M.</given-names>
</string-name>, <string-name>
<surname>Munigunti</surname>, <given-names>R.K.</given-names>
</string-name>, <string-name>
<surname>White</surname>, <given-names>E.L.</given-names>
</string-name>, <string-name>
<surname>Wilkerson</surname>, <given-names>D.C.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2015</year>) <article-title>Commercial&#x02010;scale biotherapeutics manufacturing facility for plant&#x02010;made pharmaceuticals</article-title>. <source xml:lang="en">Plant Biotechnol. J.</source>
<volume>13</volume>, <fpage>1180</fpage>&#x02013;<lpage>1190</lpage>.<pub-id pub-id-type="pmid">26387511</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0020"><mixed-citation publication-type="journal" id="pbi13194-cit-0020">
<string-name>
<surname>Jefferis</surname>, <given-names>R.</given-names>
</string-name> (<year>2005</year>) <article-title>Glycosylation of recombinant antibody therapeutics</article-title>. <source xml:lang="en">Biotechnol. Prog.</source>
<volume>21</volume>, <fpage>11</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">15903235</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0021"><mixed-citation publication-type="journal" id="pbi13194-cit-0021">
<string-name>
<surname>Jefferis</surname>, <given-names>R.</given-names>
</string-name> (<year>2012</year>) <article-title>Isotype and glycoform selection for antibody therapeutics</article-title>. <source xml:lang="en">Arch. Biochem. Biophys.</source>
<volume>526</volume>, <fpage>159</fpage>&#x02013;<lpage>166</lpage>.<pub-id pub-id-type="pmid">22465822</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0022"><mixed-citation publication-type="journal" id="pbi13194-cit-0022">
<string-name>
<surname>Kam</surname>, <given-names>Y.W.</given-names>
</string-name>, <string-name>
<surname>Simarmata</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Chow</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Her</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Teng</surname>, <given-names>T.S.</given-names>
</string-name>, <string-name>
<surname>Ong</surname>, <given-names>E.K.</given-names>
</string-name>, <string-name>
<surname>Renia</surname>, <given-names>L.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2012</year>) <article-title>Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long&#x02010;term clinical protection</article-title>. <source xml:lang="en">J. Infect. Dis.</source>
<volume>205</volume>, <fpage>1147</fpage>&#x02013;<lpage>1154</lpage>.<pub-id pub-id-type="pmid">22389226</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0023"><mixed-citation publication-type="journal" id="pbi13194-cit-0023">
<string-name>
<surname>Kam</surname>, <given-names>Y.&#x02010;W.</given-names>
</string-name>, <string-name>
<surname>Pok</surname>, <given-names>K.&#x02010;Y.</given-names>
</string-name>, <string-name>
<surname>Eng</surname>, <given-names>K.E.</given-names>
</string-name>, <string-name>
<surname>Tan</surname>, <given-names>L.&#x02010;K.</given-names>
</string-name>, <string-name>
<surname>Kaur</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>W.W.L.</given-names>
</string-name>, <string-name>
<surname>Leo</surname>, <given-names>Y.&#x02010;S.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2015</year>) <article-title>Sero&#x02010;prevalence and cross&#x02010;reactivity of chikungunya virus specific anti&#x02010;E2EP3 antibodies in arbovirus&#x02010;infected patients</article-title>. <source xml:lang="en">PLoS Negl. Trop Dis.</source>
<volume>9</volume>, <fpage>e3445</fpage>.<pub-id pub-id-type="pmid">25568956</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0024"><mixed-citation publication-type="journal" id="pbi13194-cit-0024">
<string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> (<year>2012</year>) <article-title>Bioprocessing of plant&#x02010;derived virus&#x02010;like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations</article-title>. <source xml:lang="en">Plant Cell Rep.</source>
<volume>31</volume>, <fpage>573</fpage>&#x02013;<lpage>584</lpage>.<pub-id pub-id-type="pmid">22134876</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0025"><mixed-citation publication-type="journal" id="pbi13194-cit-0025">
<string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Engle</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Fuchs</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Keller</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gorlatov</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Diamond</surname>, <given-names>M.S.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2010</year>) <article-title>Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice</article-title>. <source xml:lang="en">Proc. Natl. Acad. Sci. USA</source>, <volume>107</volume>, <fpage>2419</fpage>&#x02013;<lpage>2424</lpage>.<pub-id pub-id-type="pmid">20133644</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0026"><mixed-citation publication-type="journal" id="pbi13194-cit-0026">
<string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>He</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Engle</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Diamond</surname>, <given-names>M.S.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> (<year>2012</year>) <article-title>Robust production of virus&#x02010;like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce</article-title>. <source xml:lang="en">Plant Biotechnol. J.</source>
<volume>10</volume>, <fpage>95</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">21883868</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0027"><mixed-citation publication-type="journal" id="pbi13194-cit-0027">
<string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>He</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hurtado</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Stahnke</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Fuchs</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Mehlhop</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Gorlatov</surname>, <given-names>S.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2014</year>) <article-title>Structural and functional characterization of an anti&#x02010;West Nile virus monoclonal antibody and its single&#x02010;chain variant produced in glycoengineered plants</article-title>. <source xml:lang="en">Plant Biotechnol. J.</source>
<volume>12</volume>, <fpage>1098</fpage>&#x02013;<lpage>1107</lpage>.<pub-id pub-id-type="pmid">24975464</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0028"><mixed-citation publication-type="journal" id="pbi13194-cit-0028">
<string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Paul</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>He</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Bai</surname>, <given-names>F.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> (<year>2018</year>) <article-title>A plant&#x02010;produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity</article-title>. <source xml:lang="en">Vaccine</source>, <volume>36</volume>, <fpage>1846</fpage>&#x02013;<lpage>1852</lpage>.<pub-id pub-id-type="pmid">29490880</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0029"><mixed-citation publication-type="journal" id="pbi13194-cit-0029">
<string-name>
<surname>Leuzinger</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Dent</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hurtado</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Stahnke</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>, <given-names>X.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> (<year>2013</year>) <article-title>Efficient agroinfiltration of plants for high&#x02010;level transient expression of recombinant proteins</article-title>. <source xml:lang="en">J. Vis. Exp.</source>
<volume>77</volume>, <fpage>e50521</fpage>
<pub-id pub-id-type="doi">10.3791/50521</pub-id>
</mixed-citation></ref><ref id="pbi13194-bib-0030"><mixed-citation publication-type="journal" id="pbi13194-cit-0030">
<string-name>
<surname>Lomonossoff</surname>, <given-names>G.P.</given-names>
</string-name> and <string-name>
<surname>D'Aoust</surname>, <given-names>M.&#x02010;A.</given-names>
</string-name> (<year>2016</year>) <article-title>Plant&#x02010;produced biopharmaceuticals: A case of technical developments driving clinical deployment</article-title>. <source xml:lang="en">Science</source>, <volume>353</volume>, <fpage>1237</fpage>&#x02013;<lpage>1240</lpage>.<pub-id pub-id-type="pmid">27634524</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0031"><mixed-citation publication-type="journal" id="pbi13194-cit-0031">
<string-name>
<surname>Ma</surname>, <given-names>J.K.C.</given-names>
</string-name>, <string-name>
<surname>Drossard</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Altmann</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Boyle</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Christou</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Cole</surname>, <given-names>T.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2015</year>) <article-title>Regulatory approval and a first&#x02010;in&#x02010;human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants</article-title>. <source xml:lang="en">Plant Biotechnol. J.</source>
<volume>13</volume>, <fpage>1106</fpage>&#x02013;<lpage>1120</lpage>.<pub-id pub-id-type="pmid">26147010</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0032"><mixed-citation publication-type="journal" id="pbi13194-cit-0032">
<string-name>
<surname>Moldt</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Shibata&#x02010;Koyama</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Rakasz</surname>, <given-names>E.G.</given-names>
</string-name>, <string-name>
<surname>Schultz</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Kanda</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Dunlop</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Finstad</surname>, <given-names>S.L.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2012</year>) <article-title>A Nonfucosylated Variant of the anti&#x02010;HIV&#x02010;1 Monoclonal antibody b12 Has enhanced Fc&#x003b3;RIIIa&#x02010;mediated antiviral activity <italic>in vitro</italic> but does not improve protection against mucosal SHIV challenge in macaques</article-title>. <source xml:lang="en">J. Virol.</source>
<volume>86</volume>, <fpage>6189</fpage>&#x02013;<lpage>6196</lpage>.<pub-id pub-id-type="pmid">22457527</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0033"><mixed-citation publication-type="journal" id="pbi13194-cit-0033">
<string-name>
<surname>Montero&#x02010;Morales</surname>, <given-names>L.</given-names>
</string-name> and <string-name>
<surname>Steinkellner</surname>, <given-names>H.</given-names>
</string-name> (<year>2018</year>) <article-title>Advanced plant&#x02010;based glycan engineering</article-title>. <source xml:lang="en">Front. Bioeng. Biotechnol.</source>
<volume>6</volume>, <fpage>81</fpage>.<pub-id pub-id-type="pmid">29963553</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0034"><mixed-citation publication-type="journal" id="pbi13194-cit-0034">
<string-name>
<surname>Pal</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Dowd</surname>, <given-names>K.A.</given-names>
</string-name>, <string-name>
<surname>Brien</surname>, <given-names>J.D.</given-names>
</string-name>, <string-name>
<surname>Edeling</surname>, <given-names>M.A.</given-names>
</string-name>, <string-name>
<surname>Gorlatov</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>I.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2013</year>) <article-title>Development of a highly protective combination monoclonal antibody therapy against chikungunya virus</article-title>. <source xml:lang="en">PLoS Pathog.</source>
<volume>9</volume>, <fpage>e1003312</fpage>.<pub-id pub-id-type="pmid">23637602</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0035"><mixed-citation publication-type="journal" id="pbi13194-cit-0035">
<collab collab-type="authors">Prevail, II Writing Group</collab>
. (<year>2016</year>) <article-title>A randomized, controlled trial of ZMapp for ebola virus infection</article-title>. <source xml:lang="en">N. Engl. J. Med.</source>
<volume>375</volume>, <fpage>1448</fpage>&#x02013;<lpage>1456</lpage>.<pub-id pub-id-type="pmid">27732819</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0036"><mixed-citation publication-type="journal" id="pbi13194-cit-0036">
<string-name>
<surname>Reichert</surname>, <given-names>J.M.</given-names>
</string-name> (<year>2012</year>) <article-title>Marketing approval of mogamulizumab AU &#x02013; Beck, Alain</article-title>. <source xml:lang="en">mAbs</source>, <volume>4</volume>, <fpage>419</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">22699226</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0037"><mixed-citation publication-type="journal" id="pbi13194-cit-0037">
<string-name>
<surname>Salazar&#x02010;Gonzalez</surname>, <given-names>J.A.</given-names>
</string-name>, <string-name>
<surname>Angulo</surname>, <given-names>C.</given-names>
</string-name> and <string-name>
<surname>Rosales&#x02010;Mendoza</surname>, <given-names>S.</given-names>
</string-name> (<year>2015</year>) <article-title>Chikungunya virus vaccines: Current strategies and prospects for developing plant&#x02010;made vaccines</article-title>. <source xml:lang="en">Vaccine</source>, <volume>33</volume>, <fpage>3650</fpage>&#x02013;<lpage>3658</lpage>.<pub-id pub-id-type="pmid">26073010</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0038"><mixed-citation publication-type="journal" id="pbi13194-cit-0038">
<string-name>
<surname>Schilte</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Staikowsky</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Couderc</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Madec</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Carpentier</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Kassab</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Albert</surname>, <given-names>M.L.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2013</year>) <article-title>Chikungunya virus&#x02010;associated long&#x02010;term arthralgia: a 36&#x02010;month prospective longitudinal study</article-title>. <source xml:lang="en">PLoS Negl. Trop Dis.</source>
<volume>7</volume>, <fpage>e2137</fpage>.<pub-id pub-id-type="pmid">23556021</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0039"><mixed-citation publication-type="journal" id="pbi13194-cit-0039">
<string-name>
<surname>Shevitz</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bonham&#x02010;Carter</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lim</surname>, <given-names>J.</given-names>
</string-name> and <string-name>
<surname>Sinclair</surname>, <given-names>A.</given-names>
</string-name> (<year>2011</year>) <article-title>An economic comparison of three cell culture techniques</article-title>. <source xml:lang="en">BioPharm. Int.</source>
<volume>24</volume>, <fpage>1</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="pbi13194-bib-0040"><mixed-citation publication-type="journal" id="pbi13194-cit-0040">
<string-name>
<surname>Smith</surname>, <given-names>Scott A.</given-names>
</string-name>, <string-name>
<surname>Silva</surname>, <given-names>Laurie A.</given-names>
</string-name>, <string-name>
<surname>Fox</surname>, <given-names>Julie M.</given-names>
</string-name>, <string-name>
<surname>Flyak</surname>, <given-names>A.I.</given-names>
</string-name>, <string-name>
<surname>Kose</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Sapparapu</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Khomandiak</surname>, <given-names>S.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2015</year>) <article-title>Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus</article-title>. <source xml:lang="en">Cell. Host. Microbe.</source>
<volume>18</volume>, <fpage>86</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">26159721</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0041"><mixed-citation publication-type="journal" id="pbi13194-cit-0041">
<string-name>
<surname>Strasser</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Altmann</surname>, <given-names>F.</given-names>
</string-name> and <string-name>
<surname>Steinkellner</surname>, <given-names>H.</given-names>
</string-name> (<year>2014</year>) <article-title>Controlled glycosylation of plant&#x02010;produced recombinant proteins</article-title>. <source xml:lang="en">Curr. Opin. Biotechnol.</source>
<volume>30</volume>, <fpage>95</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">25000187</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0042"><mixed-citation publication-type="journal" id="pbi13194-cit-0042">
<string-name>
<surname>Sun</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> and <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name> (<year>2018</year>) <article-title>Development of antibody therapeutics against flaviviruses</article-title>. <source xml:lang="en">Int. J. Mol. Sci.</source>
<volume>19</volume>, <fpage>54</fpage>.</mixed-citation></ref><ref id="pbi13194-bib-0043"><mixed-citation publication-type="journal" id="pbi13194-cit-0043">
<string-name>
<surname>Tuse</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Tu</surname>, <given-names>T.</given-names>
</string-name> and <string-name>
<surname>McDonald</surname>, <given-names>K.</given-names>
</string-name> (<year>2014</year>) <article-title>Manufacturing economics of plant&#x02010;made biologics: case studies in therapeutic and industrial enzymes</article-title>. <source xml:lang="en">Biomed. Res. Int.</source>
<volume>2014</volume>, <fpage>10</fpage>.</mixed-citation></ref><ref id="pbi13194-bib-0044"><mixed-citation publication-type="journal" id="pbi13194-cit-0044">
<string-name>
<surname>Voss</surname>, <given-names>J.E.</given-names>
</string-name>, <string-name>
<surname>Vaney</surname>, <given-names>M.&#x02010;C.</given-names>
</string-name>, <string-name>
<surname>Duquerroy</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Vonrhein</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Girard&#x02010;Blanc</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Crublet</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>, <given-names>A.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2010</year>) <article-title>Glycoprotein organization of Chikungunya virus particles revealed by X&#x02010;ray crystallography</article-title>. <source xml:lang="en">Nature</source>, <volume>468</volume>, <fpage>709</fpage>.<pub-id pub-id-type="pmid">21124458</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0045"><mixed-citation publication-type="journal" id="pbi13194-cit-0045">
<string-name>
<surname>Weaver</surname>, <given-names>S.C.</given-names>
</string-name> and <string-name>
<surname>Forrester</surname>, <given-names>N.L.</given-names>
</string-name> (<year>2015</year>) <article-title>Chikungunya: evolutionary history and recent epidemic spread</article-title>. <source xml:lang="en">Antiviral Res.</source>
<volume>120</volume>, <fpage>32</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">25979669</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0046"><mixed-citation publication-type="journal" id="pbi13194-cit-0046">
<string-name>
<surname>Yang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Dent</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>H.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> (<year>2017a</year>) <article-title>Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus</article-title>. <source xml:lang="en">Vaccine</source>, <volume>35</volume>, <fpage>4287</fpage>&#x02013;<lpage>4294</lpage>.<pub-id pub-id-type="pmid">28669618</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0047"><mixed-citation publication-type="journal" id="pbi13194-cit-0047">
<string-name>
<surname>Yang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>H.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> (<year>2017b</year>) <article-title>Virus&#x02010;like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice</article-title>. <source xml:lang="en">Sci. Rep.</source>
<volume>7</volume>, <fpage>7679</fpage>.<pub-id pub-id-type="pmid">28794424</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0048"><mixed-citation publication-type="journal" id="pbi13194-cit-0048">
<string-name>
<surname>Yang</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Lai</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Hurtado</surname>, <given-names>J.</given-names>
</string-name> and <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name> (<year>2018</year>) <article-title>Plant&#x02010;produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice</article-title>. <source xml:lang="en">Plant Biotechnol. J.</source>
<volume>16</volume>, <fpage>572</fpage>&#x02013;<lpage>580</lpage>.<pub-id pub-id-type="pmid">28710796</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0049"><mixed-citation publication-type="journal" id="pbi13194-cit-0049">
<string-name>
<surname>Yoon</surname>, <given-names>I.K.</given-names>
</string-name>, <string-name>
<surname>Alera</surname>, <given-names>M.T.</given-names>
</string-name>, <string-name>
<surname>Lago</surname>, <given-names>C.B.</given-names>
</string-name>, <string-name>
<surname>Tac&#x02010;An</surname>, <given-names>I.A.</given-names>
</string-name>, <string-name>
<surname>Villa</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Fernandez</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Thaisomboonsuk</surname>, <given-names>B.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2015</year>) <article-title>High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines</article-title>. <source xml:lang="en">PLoS Negl. Trop Dis.</source>
<volume>9</volume>, <fpage>e0003764</fpage>.<pub-id pub-id-type="pmid">25951202</pub-id></mixed-citation></ref><ref id="pbi13194-bib-0050"><mixed-citation publication-type="journal" id="pbi13194-cit-0050">
<string-name>
<surname>Zeitlin</surname>, <given-names>L.</given-names>
</string-name> and <string-name>
<surname>Haydon</surname>, <given-names>H.</given-names>
</string-name> (<year>2015</year>) <article-title>Design and testing of ZMapp and manufacturing challenges</article-title>. <source xml:lang="en">Soc. Mol. Farm.</source>
<fpage>1</fpage>&#x02013;<lpage>37</lpage>.</mixed-citation></ref><ref id="pbi13194-bib-0051"><mixed-citation publication-type="journal" id="pbi13194-cit-0051">
<string-name>
<surname>Zeitlin</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Pettitt</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Scully</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Bohorova</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Pauly</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hiatt</surname>, <given-names>A.</given-names>
</string-name>
<italic>et&#x000a0;al</italic> (<year>2011</year>) <article-title>Enhanced potency of a fucose&#x02010;free monoclonal antibody being developed as an Ebola virus immunoprotectant</article-title>. <source xml:lang="en">Proc. Natl. Acad. Sci. USA</source>, <volume>108</volume>, <fpage>20690</fpage>&#x02013;<lpage>20694</lpage>.<pub-id pub-id-type="pmid">22143789</pub-id></mixed-citation></ref></ref-list></back></article>